Navigation Links
Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
Date:9/3/2012

MONTREAL and SCOTTSDALE, Ariz., Sept. 3, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) and Medicis Pharmaceutical Corporation (NYSE: MRX) today announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44.00 per share in cash. The transaction, which values Medicis' common stock at approximately $2.6 billion, was unanimously approved by the Boards of Directors of both companies.  The $44.00 per share price represents a 39% premium to Medicis' closing share price on Friday, August 31, 2012, the last trading day prior to announcement, and a 31% premium to the three-month average trading price. The transaction is expected to close in the first half of 2013.

Medicis' portfolio includes leading prescription brands SOLODYN®, RESTYLANE®, PERLANE®, ZIANA®, DYSPORT® and ZYCLARA®. The pro forma net revenue for the combined company's dermatology and aesthetics businesses for 2012 is expected to exceed $1.7 billion within the United States.

Valeant's Chairman and Chief Executive Officer, J. Michael Pearson, said, "The acquisition of Medicis represents a significant next step in our journey to become the leader in dermatology by strengthening Valeant's presence in acne, actinic keratosis, aesthetic injectables and anti-virals, among others. Medicis' highly complementary portfolio of leading branded products and promising pipeline is a solid strategic fit, and we look forward to leveraging Medicis' well known and respected name in dermatology to drive long-term growth."

Jonah Shacknai, Chairman and Chief Executive Officer of Medicis, said, "Our Board of Directors b
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
2. Valeant Pharmaceuticals To Host Investor Day
3. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
4. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
7. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
8. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
9. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
10. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
11. Global RFID in Healthcare and Pharmaceuticals Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... Inc. (Nasdaq: QCOR ) has completed a ... as its independent, registered public accounting firm for the ... BDO to replace Odenberg Ullakko Muranishi & Co. LLP ... "As we continue our strategy to grow through ...
... 4, 2011 Doctors at Beaumont Hospital, Troy ... to correct atrial fibrillation, a prevalent and growing ... is an alternative to open-heart surgery. It,s performed ... a shorter hospital stay. Phillip Robinson, ...
Cached Medicine Technology:Questcor Pharmaceuticals Selects BDO USA as its Auditor 2Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 2Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 3
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce that ... at North Carolina State’s College of Veterinary Medicine has ... for Distinguished Volunteer Service—the organization’s highest award. , ... volunteer experts to direct its work to improve the ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... finds that white women more frequently take more of ... cancer than African-American women. , African-Americans whose cancer ... to have adjuvant cancer therapy than white women, the ... remaining cancer cells, in addition to the primary therapy. ...
... months, a,perfect storm of new technology and research has ... genetics, writes Lee Silver, a professor,of molecular biology at ... is the result of an incredibly complex interplay,among the ... and even the vast stretches of "junk DNA" once ...
... a,transcript of a radio address by President Bush to ... important commitment of the Federal government is to help ... these children are,covered by Medicaid, which will spend more ... children who do not qualify for Medicaid, but whose,families ...
... Oct. 5 Marion Jones-Thompson, 31,of Austin, Texas, ... to federal agencies in connection with two investigations,conducted ... and the Northern,District of California, respectively; Michael J. ... of New York; and Scott N. Schools, the,United ...
... Why: According to the Department of Defense, the signature wound ... the conflicts in Iraq and Afghanistan ... survivors at risk of TBI. Government reports cite nearly ... service members with the potential ...
... Treatment, Physician Program at Montefiore Will, Measure Everything from ... YORK, Oct. 5 Thousands of heart patients,in the ... care in an innovative cardiovascular program in which physicians ... based on 60,performance measures for outpatient and inpatient care. ...
Cached Medicine News:Health News:Whites take supplemental breast cancer therapy more often than blacks 2Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 2Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 3Health News:NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue 4Health News:Radio Address by President Bush to the Nation 2Health News:Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations 2Health News:Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations 3Health News:Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations 4Health News:Olympic Gold Medalist Marion Jones-Thompson Pleads Guilty to Making False Statements in Two Separate Federal Criminal Investigations 5Health News:Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries 2Health News:Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries 3Health News:Novel Approach to Improving Cardiovascular Care 2Health News:Novel Approach to Improving Cardiovascular Care 3Health News:Novel Approach to Improving Cardiovascular Care 4
... temperature set by means of a ... button. A green LED indicates the ... amber LED indicates the unit has ... LED and an audible alarm indicates ...
Provides outstanding patient warming and safety throughout the hospital and is nearly half the size and one-third the weight of earlier units....
The QuickVue Advance® G. vaginalis test is an enzyme activity test for use in the detection of Gardnerella vaginalis Proline IminoPeptidase(PIP) activity in vaginal fluid specimens from women su...
The Affirm™ VPIII tests RNA probe technology offers a dependable, rapid means toward early identification and treatment of patients suffering from these pathogens....
Medicine Products: